Optimizing the Drug-like Properties of Leads in Drug Discovery
Borchardt, Ronald (EDT); Kerns, Edward (EDT); Hageman, Michael (EDT); Thakker, Dhrien (EDT); Stevens, James (EDT)
ISBN 10: 1493950479 ISBN 13: 9781493950478
Published by Springer, 2016
New
Soft cover
From
GreatBookPrices, Columbia, MD, U.S.A.
Seller rating 5 out of 5 stars
AbeBooks Seller since April 6, 2009
This specific item is no longer available.
About this Item
Description:
Seller Inventory # 28638968-n
Synopsis:
Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, “drug-like” properties refer to the molecule’s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.
"About this title" may belong to another edition of this title.
Bibliographic Details
Title: Optimizing the Drug-like Properties of Leads...
Publisher: Springer
Publication Date: 2016
Binding: Soft cover
Condition: New
Top Search Results from the AbeBooks Marketplace
Stock Image
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects, IV)
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Seller rating 5 out of 5 stars
Condition: New. In. Seller Inventory # ria9781493950478_new
Quantity: Over 20 available
Seller Image
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
Published by
Springer New York Okt 2016, 2016
ISBN 10: 1493950479
ISBN 13: 9781493950478
New
Taschenbuch
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled 'Optimizing the Drug-Like Properties of Leads in Drug Discovery,' which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process. 524 pp. Englisch. Seller Inventory # 9781493950478
Quantity: 2 available
Seller Image
"Optimizing the \"Drug-Like\" Properties of Leads in Drug Discovery"
Published by
Springer New York, Springer US Okt 2016, 2016
ISBN 10: 1493950479
ISBN 13: 9781493950478
New
Taschenbuch
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. Neuware -Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, ¿drug-like¿ properties refer to the molecule¿s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 524 pp. Englisch. Seller Inventory # 9781493950478
Quantity: 2 available
Seller Image
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
Published by
Springer New York, Springer US, 2016
ISBN 10: 1493950479
ISBN 13: 9781493950478
New
Taschenbuch
Seller: AHA-BUCH GmbH, Einbeck, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development. Seller Inventory # 9781493950478
Quantity: 1 available
Stock Image
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Paperback)
Published by
Springer-Verlag New York Inc., New York, 2016
ISBN 10: 1493950479
ISBN 13: 9781493950478
New
Paperback
Seller: Grand Eagle Retail, Bensenville, IL, U.S.A.
Seller rating 5 out of 5 stars
Paperback. Condition: new. Paperback. Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, drug-like properties refer to the molecules physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development. This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery," which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Seller Inventory # 9781493950478
Quantity: 1 available
Stock Image
Optimizing the Drug-Like Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects)
Seller: Books Puddle, New York, NY, U.S.A.
Seller rating 4 out of 5 stars
Condition: New. Seller Inventory # 26375274633
Quantity: 4 available
Stock Image
Optimizing the Drug-Like Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects)
Print on DemandSeller: Majestic Books, Hounslow, United Kingdom
Seller rating 5 out of 5 stars
Condition: New. Print on Demand. Seller Inventory # 371819350
Quantity: 4 available
Stock Image
Optimizing the Drug-Like Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects)
Print on DemandSeller: Biblios, Frankfurt am main, HESSE, Germany
Seller rating 5 out of 5 stars
Condition: New. PRINT ON DEMAND. Seller Inventory # 18375274627
Quantity: 4 available
Stock Image
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Paperback)
Published by
Springer-Verlag New York Inc., New York, 2016
ISBN 10: 1493950479
ISBN 13: 9781493950478
New
Paperback
Seller: AussieBookSeller, Truganina, VIC, Australia
Seller rating 5 out of 5 stars
Paperback. Condition: new. Paperback. Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, drug-like properties refer to the molecules physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development. This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery," which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. Seller Inventory # 9781493950478
Quantity: 1 available